Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?

RecruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

November 9, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

February 28, 2026

Conditions
Vaccination FailureVaccine Response Impaired
Interventions
DIAGNOSTIC_TEST

Serology for antibody levels - Baseline

Measurement of rubella IgG antibody levels at baseline

DIAGNOSTIC_TEST

Serology to assess cell mediated immune (CMI) response - Baseline

Assessment of cell mediated immune (CMI) response to measles, mumps, rubella, and varicella at baseline.

DIAGNOSTIC_TEST

Serology for antibody levels - Post third dose of MMR vaccine

Measurement of rubella IgG antibody levels post third dose of MMR vaccine

DIAGNOSTIC_TEST

Serology to assess CMI - Post third dose of MMR vaccine

Assessment of cell mediated response (CMI) to measles, mumps, rubella, and varicella post third dose of MMR vaccine.

Trial Locations (1)

T6G2R3

RECRUITING

University of Alberta, Edmonton

All Listed Sponsors
collaborator

Merck Canada Inc.

INDUSTRY

lead

University of Alberta

OTHER

NCT05923970 - Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta? | Biotech Hunter | Biotech Hunter